BB Biotech AG Releases 2024 Annual Report

On February 21, 2025, BB Biotech AG published its 2024 annual report. The report provides audited financial statements and insights into the biotechnology sector and the company's strategic positioning. During 2024, BB Biotech AG saw a total share return of -13.5% in CHF and -14.1% in EUR, accounting for a CHF 2.00 dividend paid in March. However, the company's Net Asset Value (NAV) increased by 3.0% in CHF and 1.7% in EUR, though it declined by 4.6% in USD.

BB Biotech AG reported a net profit of CHF 76 million in 2024, a significant turnaround from a net loss of CHF 207 million in 2023. The company plans to propose a CHF 1.80 per share dividend at the Annual General Meeting, yielding 5% based on average share price in December 2024, maintaining its consistent dividend policy. The detailed report is available online for stakeholders and investors.